DMEM, high glucose, pyruvate
Actual product may vary
Gibco™

DMEM, high glucose, pyruvate

DMEM (Dulbecco's Modified Eagle Medium) is a widely used basal medium for supporting the growth of many different mammalian cells.
Have Questions?
카탈로그 번호수량
41966029
41966-029으로도 사용됨
1 x 500 mL
카탈로그 번호 41966029
41966-029으로도 사용됨
제품 가격(KRW)
46,000
Exklusiv online
Ends: 30-Sep-2026
51,000
할인액 5,000 (10%)
Each
수량:
1 x 500 mL
Customize this product
제품 가격(KRW)
46,000
Exklusiv online
Ends: 30-Sep-2026
51,000
할인액 5,000 (10%)
Each

DMEM (Dulbecco's Modified Eagle Medium) is a widely used basal medium for supporting the growth of many different mammalian cells. Cells successfully cultured in DMEM include primary fibroblasts, neurons, glial cells, HUVECs, and smooth muscle cells, as well as cell lines such as HeLa, 293, Cos-7, and PC-12. We offer a variety of DMEM modifications for a range of cell culture applications. Find the right formulation using the media selector tool.

This DMEM is modified as follows:

With: High Glucose, L-glutamine, Phenol Red, Sodium Pyruvate

Without: HEPES

The complete formulation is available.

Using DMEM

DMEM is unique from other media as it contains 4 times the concentration of amino acids and vitamins than the original Eagle's Minimal Essential Medium. DMEM was originally formulated with low glucose (1 g/L) and sodium pyruvate, but is often used with higher glucose levels, with or without sodium pyruvate. DMEM contains no proteins, lipids, or growth factors. Therefore, DMEM requires supplementation, commonly with 10% Fetal Bovine Serum (FBS). DMEM uses a sodium bicarbonate buffer system (3.7 g/L), and therefore requires a 5–10% CO2 environment to maintain physiological pH.

For Research Use or Further Manufacturing. Not for diagnostic use or direct administration into humans or animals.
사양
세포주HeLa, 293, Cos-7 및 PC-12
세포 유형일차 섬유아세포, 뉴런, 신경아교세포, HUVECs 및 평활근 세포
농도1X
배양 환경CO2
용도(애플리케이션)Mammalian Cell Culture
형식Bottle
Glucose 농도4500 mg/L
제조 품질cGMP-compliant under the ISO 13485 standard
제품라인Gibco
제품 유형Dulbecco Modified Eagle Medium(DMEM)
수량1 x 500 mL
유통 기한12개월
배송 조건상온
분류동물 원료 성분 비함유
Culture Type포유류 세포 배양
형태액체
Serum LevelStandard Serum Supplementation
멸균멸균 여과
Sterilization MethodSterile-filtered
첨가제 포함고농도 포도당, L-글루타민, 페놀 레드, 피루브산 나트륨, Glutamine, Sodium Pyruvate, Phenol Red
첨가제 없음HEPES, No HEPES
pH7.0 to 7.4
Unit SizeEach
구성 및 보관
보관 조건: 2∼8°C. 차광 보관
배송 조건: 상온
유통 기한: 제조일로부터 12개월

자주 묻는 질문(FAQ)

What is the difference between DMEM, high glucose, pyruvate Cat. No. 41966029 and Cat. No. 11995065?

Cat. No. 41966029 is manufactured in the Paisley, Scotland facility, while Cat. No. 11995065 is dual manufactured in Grand Island, New York and Paisley, Scotland. Although the formulation is said to be equivalent for molarities, the components may differ (e.g., it could be that one used L-Cystine 2HCl the other L-Cystine). This should not affect performance. Both facilities are FDA-registered and ISO 13485 certified.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

What is the manganese concentration in DMEM? Do you offer manganese-free DMEM?

Manganese is not present in the formulation of our catalog DMEM media products.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

인용 및 참조 문헌 (2)

인용 및 참조 문헌
Abstract
Agonism and antagonism at the insulin receptor.
Authors:Knudsen L, Hansen BF, Jensen P, Pedersen TÅ, Vestergaard K, Schäffer L, Blagoev B, Oleksiewicz MB, Kiselyov VV, De Meyts P,
Journal:PLoS One
PubMed ID:23300584
'Insulin can trigger metabolic as well as mitogenic effects, the latter being pharmaceutically undesirable. An understanding of the structure/function relationships between insulin receptor (IR) binding and mitogenic/metabolic signalling would greatly facilitate the preclinical development of new insulin analogues. The occurrence of ligand agonism and antagonism is well described for G ... More
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
Authors:Jones JL, Anderson JM, Phuah CL, Fox EJ, Selmaj K, Margolin D, Lake SL, Palmer J, Thompson SJ, Wilkins A, Webber DJ, Compston DA, Coles AJ
Journal:Brain
PubMed ID:20659956
Treatment of early relapsing-remitting multiple sclerosis with the lymphocyte-depleting humanized monoclonal antibody alemtuzumab (Campath [registered trade mark]) significantly reduced the risk of relapse and accumulation of disability compared with interferon ß-1a in a phase 2 trial [Coles et al., (Alemtuzumab vs. interferon ß-1a in early multiple sclerosis. N Engl J ... More